30th Sep 2021 18:06
Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy - Proposes private placing of share to raise at least EUR8 million, which will go towards the expansion of the bexmarilimab clinical development programme and manufacturing, and the clinical development of traumakine.
Swedbank acts as lead manager and sole bookrunner for the placing.
"This fundraise will enable us to begin the MATINS Part III expansion cohorts, which we hope to convert to pivotal stage development for a regulatory submission, further our biomarker research to help us better understand which patients may benefit most from treatment with bexmarilimab and continue to support efforts to investigate bexmarilimab in additional clinical settings," says Chief Executive Officer Markku Jalkanen.
Current stock price: 375.00 pence
Year-to-date change: up 44%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Faron Pharmaceuticals